with Mucopolysaccharidosis Type II (MPS II), which is also known as Hunter syndrome. The pivotal phase of the study met its primary endpoint of patients achieving a reduction in cerebrospinal ...

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...

Despite having gone through this before with her first son, Yusof, and despite the doctors explaining that this was a gene ...

Five children under one year of age with the condition also known as mucopolysaccharidosis type II (MPS ... Children with Hunter syndrome have a missing gene, meaning they cannot produce an important ...

replacement therapy in development for MPS II (Hunter syndrome). Shares of DNLI have lost 1.9% in the past six months compared with the industry’s 8.3% decline. The FDA's above-mentioned ...

The significant partnership agreement is for the clinical development of an investigational lentiviral gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome, a rare and deadly ...

SHP609 was supposed to correct the deficiency in the iduronate-2-sulfatase enzyme in the CNS and prevent the cognitive decline seen in some Hunter Syndrome cases. Sadly, Shire said the phase 2/3 ...